DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Oncology White Paper Thumbnail with map on top

The EU5 Market Access Landspace for Oncology Drugs

By Laurie DiModica, M.S.

Global oncology sales exceeded $100 billion for the first time in 2014 and are expected to continue near double-digit annual growth through 2021, driven by the approval and uptake of targeted small molecules and biologic therapies. Innovative new treatments designed to address cancers in targeted patient populations continue to be highly valued, but the economic realities of the EU5 markets (France, Germany, Italy, Spain, and the United Kingdom), their budgetary limitations, and the increasing prevalence of many cancers, will ensure that strategies for cost-containment and efficient use of resources shape the oncology market access landscape. Beyond navigating national health technology assessment (HTA), oncology drug developers should also prepare strategies to deal with the additional market access levers and constraints to uptake that are prevalent in the EU5 markets. This will be particularly important in cases where drugs offer incremental benefit. Decision Resources Group primary research for its Access & Reimbursement portfolio (formerly European Physician & Payer Forum) highlights the impact of HTA review and national as well as subnational payer-imposed market access hurdles on oncology markets, with an emphasis on non-small cell lung cancer, prostate cancer, and colorectal cancer.

Learn more about The EU5 Market Access Landscape for Oncology Drugs by completing the form below.